State ME
Clinical Trials in Maine
Recruiting clinical trials with at least one study location in Maine. Data updated daily from ClinicalTrials.gov.
Top Conditions in Maine
Chronic Lymphocytic Leukemia (3)Small Lymphocytic Lymphoma (2)Breast Cancer (2)Acute Myeloid Leukemia (2)Atrial Fibrillation (2)Lyme Disease (1)End Stage Renal Disease (1)End Stage Liver Disease (1)Malignant Digestive System Neoplasm (1)Malignant Female Reproductive System Neoplasm (1)Malignant Genitourinary System Neoplasm (1)Cardiovascular Disease (1)
Frequently Asked Questions — Clinical Trials in Maine
How many clinical trials are currently recruiting in Maine?
ClinicalMetric currently tracks 38 actively recruiting clinical trials with at least one location in Maine. The total number of registered studies—including active but not currently enrolling trials—is 38. Trial availability is updated daily from ClinicalTrials.gov, and new studies open enrollment regularly throughout the year.
What types of clinical trials are available in Maine?
Maine hosts clinical trials across a broad range of medical conditions, including Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Breast Cancer, and many others. Trials range from Phase 1 early-safety studies to Phase 4 post-approval surveillance, as well as observational and behavioral research. Academic medical centers, community hospitals, and specialized research clinics throughout Maine serve as trial sites for studies sponsored by NIH, pharmaceutical companies, and independent investigators.
How do I join a clinical trial near me in Maine?
To join a clinical trial in Maine, browse the recruiting studies listed on this page, review the eligibility criteria for each trial, and contact the study site directly. Your primary care physician or specialist can also refer you to clinical trials relevant to your diagnosis. Many academic medical centers in Maine maintain dedicated clinical trials offices that can match you with appropriate studies based on your medical profile and diagnosis.
Recruiting Trials in Maine
NCT07500506 Phase 3
Recruiting
A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth D...
Condition
Lyme Disease
Enrollment
1,712 pts
Location
United States, Canada
Sponsor
Pfizer
NCT03803423 N/A
Recruiting
Dissemination of the Donor Application: Utilizing Social Media to Identify Poten...
Condition
End Stage Renal Disease
Enrollment
1,000 pts
Location
United States
Sponsor
Johns Hopkins University
NCT07215624 N/A
Recruiting
Surgical Thromboprophylaxis Practices in Oncology Patients Within the NCORP Netw...
Condition
Malignant Digestive System Neoplasm
Enrollment
500 pts
Location
United States, Puerto Rico
Sponsor
Wake Forest University Health
NCT06333262 Phase 2
Recruiting
Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia
Condition
Chronic Lymphocytic Leukemia
Enrollment
60 pts
Location
United States
Sponsor
Inhye Ahn
NCT04269902 Phase 3
Recruiting
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia...
Condition
Chronic Lymphocytic Leukemia
Enrollment
247 pts
Location
United States, Canada
Sponsor
National Cancer Institute (NCI
NCT07000357 Phase 3
Recruiting
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a Histo...
Condition
Cardiovascular Disease
Enrollment
15,100 pts
Location
United States, Argentina, Brazil
Sponsor
AstraZeneca
NCT06052267 Phase 3
Recruiting
A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol ...
Condition
Asthma
Enrollment
2,700 pts
Location
United States, Argentina, Australia
Sponsor
Teva Branded Pharmaceutical Pr
NCT06348238 N/A
Recruiting
Strategies to Improve Well-Being and Diabetes Management
Condition
Diabetes Mellitus, Type 2
Enrollment
150 pts
Location
United States
Sponsor
Elizabeth Scharnetzki
NCT03488693 Phase 3
Recruiting
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
Condition
Breast Cancer
Enrollment
2,140 pts
Location
United States, Canada
Sponsor
Canadian Cancer Trials Group
NCT06758401 Phase 3
Recruiting
This is a Study to Learn About How the Combination of the Study Medicines Sigvot...
Condition
Non-Small Cell Lung Cancer
Enrollment
714 pts
Location
United States, Argentina, Australia
Sponsor
Pfizer
NCT04968834 N/A
Recruiting
Protocol For Genomically Profiling, Collecting, Archiving And Distributing Blood...
Condition
Leukemia
Enrollment
300 pts
Location
United States
Sponsor
Dana-Farber Cancer Institute
NCT07103733 N/A
Recruiting
PRIMARY Ancillary Substudy
Condition
Mitral Valve Prolapse
Enrollment
250 pts
Location
United States, Germany, United Kingdom
Sponsor
Annetine Gelijns
NCT05334069 N/A
Recruiting
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests...
Condition
Acute Lymphoblastic Leukemia
Enrollment
2,000 pts
Location
United States
Sponsor
Alliance for Clinical Trials i
NCT06494904 Phase 3
Recruiting
Standard Versus High Dose ED-Initiated Buprenorphine Induction
Condition
Opioid Use Disorder
Enrollment
360 pts
Location
United States
Sponsor
Yale University
NCT06172296 Phase 3
Recruiting
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Tre...
Condition
Ganglioneuroblastoma, Nodular
Enrollment
478 pts
Location
United States, Australia, Canada
Sponsor
National Cancer Institute (NCI
NCT06777368 N/A
Recruiting
REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failu...
Condition
Aortic Stenosis
Enrollment
225 pts
Location
United States
Sponsor
Medtronic Cardiovascular
NCT05946213 Phase 3
Recruiting
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in...
Condition
Prostate Adenocarcinoma
Enrollment
1,209 pts
Location
United States, Canada, Hong Kong
Sponsor
NRG Oncology
NCT06635148 Phase 2
Recruiting
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Part...
Condition
Geographic Atrophy
Enrollment
274 pts
Location
United States, Australia, Belgium
Sponsor
Janssen Research & Development
NCT06291376 Phase 3
Recruiting
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
Condition
Immunoglobulin A Nephropathy
Enrollment
510 pts
Location
United States, Argentina, Australia
Sponsor
Alexion Pharmaceuticals, Inc.
NCT06247085 Phase 3
Recruiting
A Study to Investigate Efficacy and Safety of Pegtibatinase Compared With Placeb...
Condition
Homocystinuria
Enrollment
70 pts
Location
United States, Australia, Belgium
Sponsor
Travere Therapeutics, Inc.
NCT06064877 Phase 3
Recruiting
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recur...
Condition
Metastatic Head-and-neck Squamous-cell Carcinoma
Enrollment
410 pts
Location
United States, Australia, Belgium
Sponsor
AVEO Pharmaceuticals, Inc.
NCT06958328 Phase 3
Recruiting
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
Condition
Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma
Enrollment
356 pts
Location
United States
Sponsor
NRG Oncology
NCT05836987 Phase 3
Recruiting
The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial F...
Condition
Atrial Fibrillation
Enrollment
5,350 pts
Location
United States
Sponsor
Johns Hopkins University
NCT04852887 Phase 3
Recruiting
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, O...
Condition
Stage I Breast Cancer
Enrollment
1,670 pts
Location
United States, Canada, Hong Kong
Sponsor
NRG Oncology
NCT04893109 Phase 2
Recruiting
ATEMPT 2.0: Adjuvant T-DM1 vs TH
Condition
Breast Cancer
Enrollment
500 pts
Location
United States
Sponsor
Dana-Farber Cancer Institute
Page 1 of 2 — 38 trials total
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology